Cognitive and neuroprotective peptides
This bucket collects findings on peptides used for cognition, focus, and neuroprotection. Coverage is deepest for selank and semax, with a smaller body of evidence on cerebrolysin. Evidence quality varies widely across these compounds, and the tier is shown against each finding below.
Much of the selank and semax literature originates from Russian clinical trials that are not indexed in Western databases, which is a real limitation on how far these results should be generalised.
Selank
Selank is an anxiolytic peptide derived from tuftsin, used as a prescription anxiety medication in Russia. The reported profile is anxiety reduction without the sedation, tolerance, or withdrawal associated with benzodiazepines.
| Finding | Evidence | Source |
|---|---|---|
| Selank approved as prescription anxiety medication in Russia since 2011 Selank has been used in Russia as a prescription medication for over two decades and has been on their official list of vital and essential medicines since 2011. It is approved for generalized anxiety disorder and neuras | human-obs | source |
| Selank modulates GABA system differently than benzodiazepines Research by Kassian et al. (2017) showed Selank enhances the anxiolytic effect of GABA signaling through a different binding mechanism than benzodiazepines. Rather than forcing GABA-A receptors to open more aggressively, | RCT | source |
| Selank alters expression of 45 GABA-related genes within 1 hour A 2016 study by Volkova confirmed that Selank changes the expression of 45 out of 84 genes involved in GABA function in the brain. The pattern of gene expression changes matched what occurred when GABA itself was adminis | animal | source |
| Selank matched benzodiazepine Medazepam for anxiety with added anti-fatigue effects A clinical trial by Zozulya et al. (2008) compared Selank directly to Medazepam (a benzodiazepine commonly used in Russia). Anxiolytic effects were similar between the two, but Selank also demonstrated anti-fatigue and m | RCT | source |
| Selank anxiolytic effects persist up to one week after cessation A clinical trial by Medvedev et al. (2014) compared Selank to Phenazepam (a Russian benzodiazepine) and found comparable anxiety reduction. Notably, the anxiolytic effect from Selank persisted for up to one week after th | RCT | source |
| Selank does not cause tolerance, dependence, or withdrawal Clinical trials observed no tolerance, dependence, or withdrawal with Selank use. Because Selank modulates the existing GABA system rather than artificially forcing receptor activity, the brain does not compensate by dow | RCT | source |
| Selank upregulates BDNF in the hippocampus Selank upregulates brain-derived neurotrophic factor (BDNF), particularly in the hippocampus. BDNF supports neuron survival, neurogenesis, and synaptic plasticity. Since chronic anxiety suppresses BDNF and low BDNF worse | animal | source |
| Selank influences serotonin, dopamine, and norepinephrine Beyond GABA modulation, Selank influences monoamine neurotransmitters including serotonin, dopamine, and norepinephrine. This monoamine modulation may contribute to the mood and focus improvements reported by users beyon | animal | source |
| Selank dosage protocol: 150-300 mcg intranasal 2-3x daily, cycled Selank is primarily administered intranasally (nasal spray or drops) as it crosses the blood-brain barrier directly through nasal passages. Subcutaneous injection is also possible for more precise dosing. Oral administra | expert-opinion | source |
| Selank safety profile and contraindications Selank has a minimal side effect profile. The most common side effects are mild nasal irritation from the spray and occasional mild headache. No sedation, cognitive impairment, or motor coordination effects are reported. | expert-opinion | source |
| Selank evidence limited to Russian clinical trials All human clinical data on Selank comes from Russian studies. There are no published Western clinical trials as of the video's recording. Sample sizes are smaller than what would typically be required for FDA approval. T | expert-opinion | source |
| Selank Reduces Anxiety Without Sedation or Dependence Selank has been demonstrated in both human and animal studies to reduce anxiety and stress without causing the drowsiness, tolerance, or dependence commonly associated with benzodiazepines. Users experience calm focus ra | human-obs | source |
Semax
Semax is an ACTH fragment analogue used for focus and cognitive performance. The reported mechanism centres on BDNF upregulation rather than stimulant action.
| Finding | Evidence | Source |
|---|---|---|
| Peptides vs Supplements for Cognitive Enhancement — Dihexa, P21, Semax, Selank Supplement formulator compares neuropeptides to traditional nootropics. Dihexa described as 'hundreds of times more powerful than lion's mane' for neurogenesis. P21+Dihexa combined in 'Neurorigen' product. Semax compared | clinical-anecdotal | source |
| Semax mechanism: BDNF upregulation strengthens synapses Semax is a seven amino acid synthetic peptide analog of ACTH (not FDA approved). Its primary proposed mechanism is increasing the activity and abundance of BDNF (brain-derived neurotrophic factor), which strengthens syna | expert_explanation | source |
| Semax enhances focus without stimulant effects Semax enhances focus, learning, and mental clarity without stimulant properties. Unlike caffeine or amphetamines, it does not increase blood pressure or produce a wired feeling. Users report improved task performance, be | clinician_report | source |
| Semax vs Selank: cognitive vs psychiatric focus Semax and Selank are described as sister peptides with different primary applications. Selank is more helpful for anxiety and depression (psychiatric-focused), while Semax targets brain fog, attention, high cognitive dem | clinician_report | source |
| Semax clinical indications and dosing protocol Clinical indications: cognitive enhancement, anxiety/depression management, ischemic stroke recovery, ADHD, neuroprotection, optic nerve disorders, chronic fatigue, and pain management. Nasal spray dosing: start 300mcg/d | clinician_report | source |
| Semax multi-pathway mechanism of action Semax works through multiple pathways: increases BDNF for neuronal growth/protection, modulates dopaminergic and serotonergic systems for mood and cognition, improves cerebral blood flow, has antioxidant properties prote | clinician_report | source |
| Semax upregulates BDNF and NGF via melanocortin receptors Semax binds to melanocortin receptors MC3 and MC4 in the hippocampus and prefrontal cortex, initiating transcriptional upregulation of genes coding for BDNF and NGF. This constructs physical infrastructure for better mem | expert_explanation | source |
| Semax addresses three pillars of cognitive decline Semax targets three fundamental biological failures causing cognitive decline: (1) Inflammatory firestorm — reduces NF-kappa-B signaling and pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) that cross the blood-bra | expert_explanation | source |
| Semax for neurodegenerative diseases: Alzheimer, Parkinson, MS Semax applications in neurodegeneration: For Alzheimer's, enhances non-amyloidogenic pathway, reduces toxic peptide production, upregulates neprilysin to degrade existing amyloid. For dementia, BDNF surge activates TrkB | expert_explanation | source |
| Semax protocol: 4 weeks on, 2 weeks off Recommended cycling protocol is 4 weeks on, 2 weeks off to prevent receptor downregulation and maintain efficacy. Continuous use is not recommended. For maximum cognitive benefit, combine with Cerebrolysin (direct neurot | expert_explanation | source |
| Semax increases BDNF by 1.4x and doubles neuroprotective gene expression Research shows Semax increases BDNF levels by 1.4 times and doubles the expression of certain neuroprotective genes. BDNF stimulation is considered the holy grail for eliminating brain fog and mitigating neurocognitive d | clinician_report | source |
| Semax for type 2/type 3 diabetes and brain rewiring Semax improves brain function and network firing in patients with blood sugar issues. Type 2 diabetes can progress to type 3 diabetes (early onset Alzheimer's) when inadequate cerebral blood flow impairs neural pathway f | clinician_report | source |
Cerebrolysin
Cerebrolysin is a neuropeptide complex given by intramuscular injection, studied mainly in traumatic brain injury and stroke recovery. It is the most invasive option in this group and the one with the most restrictive availability.
| Finding | Evidence | Source |
|---|---|---|
| Cerebrolysin: Neuropeptide Complex — Benefits, Dosage, and Protocol Cerebrolysin is a complex neuropeptide mixture (not a single peptide) derived from enzymatic hydrolysis of porcine brain tissue. Composition: ~75% free L-amino acids + ~25% low-MW neuropeptides (BDNF, NGF, CNTF, GDNF fra | source | |
| Cerebrolysin Lyophilized Powder — Product Specs & Storage (EliteBioGenix) EliteBioGenix sells Cerebrolysin as lyophilized powder in 50mg and 60mg vials. Storage: 2-8°C or -20°C, protect from light, avoid repeated freeze-thaw. No reconstitution instructions provided on product page. In-vitro re | product-info | source |
| Cerebrolysin 60mg Lyophilized Vial — Reconstitution & SubQ Dosing Protocol Reconstitution protocol for 60mg lyophilized Cerebrolysin: Add 3.0 mL bacteriostatic water (inject slowly down vial wall, gently swirl, do not shake) → 20 mg/mL concentration. SubQ injection at 45-90°. Titration: Week 1: | community-protocol | source |
| Cerebrolysin for TBI/Stroke — International Availability Discussion Longevity medicine physician discusses Cerebrolysin as standard TBI/stroke treatment in Austria. Notes it's a mix of ~50 peptides that repairs neurons, unavailable in US due to regulatory burden of approving each peptide | clinical-anecdotal | source |
| Neuroprotective Effects of Cerebrolysin in Moderate TBI with Nonoperative Lesions: 6-Month Prospective Cohort Prospective single-blind controlled cohort (n=340) from Thailand. Cerebrolysin 30mL/day IV for 10 days in moderate TBI with nonoperative ICH. Significant improvement in CRS-R scores at discharge (20.3±2.7 vs 16.4±2.1, p= | observational | source |
| Cerebrolysin as a Multi-Peptide Neuroprotective Agent Used in Austrian Hospitals Cerebrolysin is described as a mixture of approximately 50 different peptides that functions to repair neurons. It is widely used in Austria as a standard-of-care treatment for traumatic brain injury and stroke, administ | expert-opinion | source |
| FDA Regulatory Barrier Preventing Cerebrolysin Approval in the U.S. The speaker explains that Cerebrolysin's approximately 50-peptide composition creates an insurmountable regulatory obstacle in the United States, as each individual peptide would require its own separate FDA authorizatio | expert-opinion | source |
| Cerebrolysin IV Infusion for Cognitive Improvement and Ischemic Stroke Clinical Trial Dr. Pradeep Albert discusses cerebrolysin as a neuropeptide growth factor containing three growth factors. He reports running a clinical trial using cerebrolysin on patients with recent ischemic strokes, noting it addres | human-obs | source |
| Intramuscular ARA-290 and Cerebrolysin for Acute Neurological Movement Disorder A college student presenting with involuntary arm movements received intramuscular injections of both ARA-290 and Cerebrolysin. According to the clinician's account, her symptoms resolved rapidly — within the time it too | anecdotal | source |
| Peptides as a General Class Possess Potent Nerve-Treating Abilities The clinician offers a broad expert opinion that peptides as a class demonstrate powerful nerve-treating and neuroprotective abilities, though he acknowledges they do not help every condition. This claim is based on his | expert-opinion | source |